Key Highlights

  • Third-quarter Revenue totaled USD 302.3 million, up from USD 229.0 million, a jump of roughly 32% (calculated).
  • Earnings attributable to the company came to USD 9.6 million, or USD 0.26 a diluted share, versus USD 6.1 million, or USD 0.17 a year before.
  • Consolidated adjusted EBITDA increased to USD 24.7 million from USD 17.3 million, and Operating Income advanced to USD 16.5 million from USD 10.2 million.
  • Debt rose to USD 199.3 million at September 30, 2026 from USD 175.0 million at year-end, with net interest expense at USD 3.6 million for the quarter.

Purchased Home Health Operations Propel Top-Line Growth

The Pennant Group (NASDAQ:PNTG) lodged its quarterly filing on November 4, 2026, for the period ending September 30. Quarterly sales came in at USD 302.3 million, above the USD 229.0 million of the prior-year quarter, and nine-month sales reached USD 885.6 million versus USD 658.4 million. The home health and hospice line brought in USD 239.8 million, compared with USD 173.5 million, while senior living generated USD 60.6 million, up from USD 53.9 million. Home health admissions advanced to 28,479 from 20,426, and Medicare admissions grew to 11,347 from 8,221. Nine-month operating income reached USD 51.0 million, a step up from USD 34.4 million, a period that followed the purchase, effective October 1, 2025, of operations taken over from UnitedHealth, Amedisys and additional sellers.

Margin Gains Offset by Higher Interest and Transition Costs

Operating income represented 5.5% of revenue, compared with 4.4% previously, as general and administrative expense shrank to 6.8% of revenue from 8.4%. Cost of services, though, climbed to 82.1% of revenue from 81.0%. Segment adjusted EBITDAR for home health and hospice climbed to USD 41.4 million from USD 29.1 million, and senior living moved to USD 16.2 million from USD 15.3 million. Net interest expense rose to USD 3.6 million from USD 1.0 million, more than tripling (calculated), and a transition services arrangement with UnitedHealth absorbed USD 1.6 million in the quarter. An Equity method holding added USD 1.4 million, and share-based pay came to USD 3.4 million, compared with USD 2.5 million. The average Medicare payment for each completed home health episode eased to USD 3,632 from USD 3,712.

Borrowings, Payer Exposure and the Earnings Trajectory

Borrowings split into USD 103.0 million on the revolver and USD 96.3 million in incremental term loans. Profit attributable to the company grew about 58% (calculated). Nine-month Net Income was USD 27.2 million, or USD 0.76 a diluted share, compared with USD 20.9 million, or USD 0.59. The company runs home health, hospice and senior living operations, and the filing names Medicare and Medicaid rate changes, proposed federal cuts to Medicare, staffing regulations and integration of acquisitions as principal risks. The reviewed sections include no earnings guidance, so forward expectations are not quantified in this article. Nine-month consolidated adjusted EBITDA reached USD 70.7 million, versus USD 50.1 million, and weighted diluted shares increased to 36.4 million from 35.3 million. Medicare exposure runs through much of these figures.

Where Things Stand

Most revenue growth reached profit, though not all of it. Sales expanded about 32% (calculated), while profit attributable to the company increased roughly 58%, aided by lower overhead as a share of revenue. Debt and interest costs both moved higher for The Pennant Group (NASDAQ:PNTG), and revenue per Medicare episode slipped. Looking ahead, investors will follow how the acquired operations integrate, when UnitedHealth transition fees end, Medicare reimbursement proposals and fourth-quarter results.